H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Tyra Biosciences to $15 from $12 and keeps a Buy rating on the shares after the company announced TYRA-300 will be developed in achondroplasia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TYRA: